Clinical Trials Logo

Clinical Trial Summary

In this study we aimed to assess the clinical and laboratory profile of some Egyptian asthmatic children who are sensitized to house dust mites and determine the association of HDM sensitization and severity of asthma according to recent GINA guidelines.


Clinical Trial Description

This is an observational, case control study. The study was carried out in Allergy, Clinical Immunology and pediatric pulmonology Unit; at Mansoura University Children Unit during the years 2018-2019. The study included 60 children above 6 years with atopic asthma. They were 42 males and 18 females, their age ranged from 8-17 years. Bronchial asthma diagnosis was based on clinical manifestations and spirometry results. Atopy was defined as presence of symptoms of atopic dermatitis, allergic rhino conjunctivitis, or food allergy, it was confirmed when asthmatic children fulfilled one of the following criteria: higher serum level of total IgE (more than 32IU/ml), eosinophilia (differential count more than 5% or absolute count more than 450/µl) or positive skin prick test (3 mm greater than control). Asthmatic children were maintained on controller therapy for at least 6 months. They were classified according to skin prick test results into two groups: - Group1: It included 30 atopic asthmatic children, who were sensitive to one of the two HDM (D pteronyssinus or D farina). - Group2: It included 30 atopic asthmatic children who were not sensitive to HDM allergy. - Sampling Samples were convenient and patients were enrolled in the study by consecutive manner. history taking - Personal and demographic data e.g. age, sex and residence. - Asthma symptoms; cough, wheeze, as well as exercise-induced asthma. - Symptoms of other atopic diseases in the child including allergic march. - Based on frequency of each symptom, assessment of asthma control was done according to GINA 2017. Pulmonary Function Test (Spirometry) Forced expiratory volume in 1 second FEV1%; forced vital capacity (FVC %); FEV1/FVC ratio and forced expiratory flow rate from 25% to 75% of vital capacity (FEF25-75%) were measured by spirometry (Master Screen pediatrics). The highest reading of three successive measurements was taken. Reference values were computed according to the recommendations of the American Thoracic Society standards of acceptability and reproducibility in subjects above the age of 6 years who need cooperation for forced respiratory maneuver. Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation). 3- Eosinophil count Blood sample was collected in EDTA tube. Total leucocytic count and eosinophilia % were determined by automated cell counter [11]. 4- Serum IgE Blood samples were collected into tubes with ethylene tetr-acetic acid (EDTA). After incubation at room temperature for 20 minutes, tubes were centrifuged for 15 minute at 2500 revolutions per minute (rpm). Supernatant levels of IgE were determined by the ELISA technique [12]. Assessment level of asthma severity Classification of asthma according to disease severity is defined level (mild, moderate, severe) according to treatment steps when the patient has been maintained on regular controller therapy for several months. Patient maintained on step 2 treatments are often classified as having mild asthma. Those receive step 3-4 as moderate asthma and those prescribed step 4-5 as having moderate to severe asthma [2]. I) Assessment level of asthma control based on asthma control score according to GINA guideline defined as controlled, partially controlled and well controlled . Statistical analysis Data were fed to the computer and analyzed using IBM SPSS Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp. The following tests were used: Qualitative data: Chi-Square test for comparison of 2 or more groups. Monte Carlo test as correction for Chi-Square test when more than 25% of cells have count less than 5 in tables (>2*2). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04958616
Study type Observational
Source Mansoura University Children Hospital
Contact
Status Completed
Phase
Start date February 1, 2018
Completion date March 1, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT02934945 - Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients Phase 4
Completed NCT02561351 - Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation N/A
Recruiting NCT01759472 - Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test N/A
Completed NCT01918293 - Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult N/A
Completed NCT01203904 - Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation N/A
Completed NCT01762917 - Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing N/A
Completed NCT00536731 - Symbicort Rapihaler Therapeutic Equivalence Study Phase 3
Completed NCT00930826 - Childhood Asthma and Schooling: The Truth Unveiled N/A
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00327028 - Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma Phase 4
Completed NCT00413387 - Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®) Phase 3
Completed NCT00950794 - Study of Salmeterol (SN408D) for Adult Asthma Phase 4
Completed NCT00153283 - Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma Phase 4
Completed NCT00142025 - Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma Phase 4
Completed NCT00153270 - Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma Phase 4
Completed NCT03450434 - XC8 in the Treatment of Patients With Bronchial Asthma Phase 2
Recruiting NCT05189613 - Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis N/A
Recruiting NCT04128111 - Study on the Correlation Between TCM Syndrome, Inflammatory Phenotype and Biomarker of Bronchial Asthma
Completed NCT06326632 - Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma N/A
Completed NCT05088512 - The Role of Genetic Factors in the Development of Bronchial Asthma in the Kazakh Population